Sanofi-aventis Withdraws Its Marketing Authorisation Application ForAquilda (satavaptan), Europe

The European Medicines Agency (EMEA) has been formally notified by Sanofi-Aventis of its decision to withdraw the application for a centralised marketing authorisation for the medicine Aquilda (satavaptan) 5 and 25 mg film-coated tablets. Aquilda was intended to be used for the treatment of euvolaemic and hypervolaemic dilutional hyponatraemia, a metabolic condition in which the body’s blood sodium level falls below normal.

More: continued here

Filed under: Blood on June 1st, 2008